Progress in Vaccination against type b in the Americas

1. World Health Organization

2006

WHO Position Paper on Haemophilus influenzae type b conjugate vaccines.

Wkly Epidemiol Rec

81

445

452

2. WengerJDWardJI

2004

Haemophilus

influenzae vaccine.

In

PlotkinSAOrensteinWA

editors

Vaccines

4th edition

Philadelphia

W. B. Saunders Co

229

268

3. Pan American Health Organization

2005

Control of diphtheria, pertussis, tetanus, Haemophilus influenzae type b, and

hepatitis B. Field guide.

Available http://www.ops-oms.org/English/AD/FCH/IM/fieldguide_pentavalent.pdf.

Accessed 6 March 2008

4. EskolaJPeltolaHTakalaAKKayhtyHHakulinenM

1987

Efficacy of Haemophilus

influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine

in infancy.

N Engl J Med

317

717

722

5. BooyRMoxonERMacFarlaneJAMayon-WhiteRTSlackMP

1992

Efficacy of Haemophilus

influenzae type B conjugate vaccine in Oxford region.

Lancet

340

847

6. VadheimCMGreenbergDPPartridgeSJingJWardJI

1993

Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young

infants. Kaiser-UCLA Vaccine Study Group.

Pediatrics

92

272

279

7. MulhollandKHiltonSAdegbolaRUsenSOparaugoA

1997

Randomised trial of Haemophilus

influenzae type-b tetanus protein conjugate vaccine

[corrected] for prevention of pneumonia and meningitis in Gambian

infants.

Lancet

349

1191

1197

Erratu In: Lancet 1997;350(9076):524

8. SwinglerGFransmanDHusseyG

2003

Conjugate vaccines for preventing Haemophilus influenzae type b infections.

Cochrane Database Syst Rev

CD001729

9. MurphyTVWhiteKEPastorPGabrielLMedleyF

1993

Declining incidence of Haemophilus influenzae type b disease since introduction of

vaccination.

JAMA

269

246

248

10. Pan American Health Organization

1996

Impact of Uruguay's introduction of the Haemophilus influenzae type b (Hib)

vaccine.

EPI Newsletter

18

6

11. WengerJDDiFabioJLandaverdeJMLevineOSGaafarT

1999

Introduction of Hib conjugate vaccines in the non-industrialized world:

experience in four ‘newly adopting’ countries.

Vaccine

18

736

742

12. HeathPTMcVernonJ

2002

The UK Hib vaccine experience.

Arch Dis Child

86

396

399

13. AdegbolaRASeckaOLahaiGLloyd-EvansNNjieA

2005

Elimination of Haemophilus

influenzae type b (Hib) disease from The Gambia after the introduction

of routine immunisation with a Hib conjugate vaccine: a prospective study.

Lancet

366

144

150

14. TakalaAKEskolaJLeinonenMKayhtyHNissinenA

1991

Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in

children immunized with an Hib conjugate vaccine.

J Infect Dis

164

982

986

15. MurphyTVPastorPMedleyFOsterholmMTGranoffDM

1993

Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate

vaccine.

J Pediatr

122

517

523

16. HviidAMelbyeM

2004

Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine.

Vaccine

22

378

382

17. World Health Organization

2008

Haemophilus

influenzae type b vaccine.

Available http://www.who.int/immunization/topics/hib/en/index.html. Accessed 6 March

2008

18. The Hib Initiative

2008

About the Hib Initiative: Vision.

Available: http://www.hibaction.org/abouthibinitiative.php#vision. Accessed 6 March

2008

19. PeltolaH

1997

Haemophilus

influenzae type b disease and vaccination in Latin America and the

Caribbean.

Pediatr Infect Dis J

16

780

787

20. CochiSLO'MaraDPrebludSR

1988

Progress in Haemophilus type b polysaccharide vaccine use in the United States.

Pediatrics

81

166

168

21. World Health Organization

2002

Haemophilus

influenzae type b (Hib) meningitis in the pre-vaccine era. A global

review of incidence, age distributions, and case-fatality rates.

Available http://www.who.int/immunization/documents/WHO_VB_02.18/en/index.html.

Accessed 6 March 2008

22. TambiniGAndrusJKFitzsimmonsJWRoses PeriagoM

2006

Regional immunization programs as a model for strengthening cooperation

among nations.

Rev Panam Salud Publica

20

54

59

23. DeRoeckDBawazirSACarrascoPKaddarMBrooksA

2006

Regional group purchasing of vaccines: Review of the Pan American Health

Organization EPI revolving fund and the Gulf Cooperation Council group purchasing

program.

Int J Health Plann Manage

21

23

43

24. World Health Organization

1983

EPI in the Americas: benefits from the Revolving Fund.

WHO Chronicle

37

81

85

25. LandaverdeMDi FabioJLRuoccoGLealIde QuadrosC

1999

Introduction of a conjugate vaccine against Hib in Chile and Uruguay.

Rev Panam Salud Publica

5

200

206

26. Pan American Health Organization

2004

Comparison of three alternatives for administering DTP, Haemophilus influenzae type b, and

hepatitis B vaccines through the Expanded Program on Immunization (EPI) in Bolivia.

EPI Newsletter

26

4

6

27. World Health Organization

1992

Informal discussion on quadrivalent diphtheria-tetanus-pertussis-hepatitis B

vaccine

Final report

Geneva

World Health Organization

28. SantosJILevineO

2006

Combination vaccines for childhood immunization.

In

AndrusJKde QuadrosC

editors

Recent Advances in Immunization

2nd edition

Washington (D. C.)

Pan American Health Organization

30

48

29. HadlerSC

1994

Cost benefit of combining antigens.

Biologicals

22

415

418

30. Di FabioJLde QuadrosC

2001

Considerations for combination vaccine development and use in the

developing world.

Clin Infect Dis

33

Suppl 4

S340

S345

31. HayJWDaumRS

1990

Cost-benefit analysis of Haemophilus influenzae type b prevention: Conjugate vaccination at

eighteen months of age.

Pediatr Infect Dis J

9

246

252

32. LevineOSOrtizEContrerasRLagosRVialP

1993

Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate

vaccine in Santiago, Chile.

Am J Epidemiol

137

1221

1228

33. ZhouFBisgardKMYusufHRDeusonRRBathSK

2002

Impact of universal Haemophilus

influenzae type b vaccination starting at 2 months of age in the

United States: An economic analysis.

Pediatrics

110

653

661

34. AndrusJKFitzsimmonsJde QuadrosC

2006

Introduction of new and underutilized vaccines: perspectives from the

Americas.

In

AndrusJKde QuadrosC

editors

Recent Advances in Immunization

2nd edition

Washington (D. C.)

Pan American Health Organization

114

26

35. Pan American Health Organization

2007

Informe Regional de SIREVA II: Datos por país y por grupos de edad

sobre las características de los aislamientos de Streptococcus

pneumoniae, Haemophilus influenzae y Neisseria

meningitidis, en procesos invasores, 2000–2005

Washington (D. C.)

Pan American Health Organization

36. Vaccines and Immunization

2000

In the 42nd Meeting Pan American Directing Council, Washington DC, Sep

2000. Resolution CD42/R8. Pan American Health Organization.

Available: http://www.paho.org/english/gov/cd/cd42_fr-e.pdf. Accessed 6 March

2008

37. AndrusJKTambiniGdi FabioJLPeriagoMR

2004

Anticipating new vaccines in the Americas.

Rev Panam Salud Publica

16

369

370

38. Pan American Health Organization

2006

Regional strategy for sustaining National Immunization Programs in the

Americas.

Working document presented at the 138th Executive Committee. Available: http://www.paho.org/English/GOV/CE/ce138-11-e.pdf. Accessed 6 March

2008

39. AndrusJKToscanoCLewisMOliveiraLRoperoAM

2007

A model for enhancing evidence-based capacity to make informed policy

decisions on the introduction of new vaccines in the Americas: PAHO's PROVAC initiative.

Public Health Rep

122

811

816

40. RibeiroGSLimaJBReisJNGouveiaELCordeiroSM

2007

Haemophilus

influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate

vaccine in Brazil.

Vaccine

25

4420

4428

41. LagosRHorwitzIToroJSan MartinOAbregoP

1996

Large scale, postlicensure, selective vaccination of Chilean infants with

PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive

Haemophilus influenzae

type b infections.

Pediatr Infect Dis J

15

216

222

42. LevineOSLagosRMunozAVillaroelJAlvarezAM

1999

Defining the burden of pneumonia in children preventable by vaccination

against Haemophilus

influenzae type b.

Pediatr Infect Dis J

18

1060

1064

43. de AndradeALde AndradeJGMartelliCMde SilvaSAde OliveiraRM

2004

Effectiveness of Haemophilus

influenzae b conjugate vaccine on childhood pneumonia: A case-control

study in Brazil.

Int J Epidemiol

33

173

181

44. de la HozFHigueraABDi FabioJLLunaMNaranjoAG

2004

Effectiveness of Haemophilus

influenzae type b vaccination against bacterial pneumonia in Colombia.

Vaccine

23

36

42

45. World Health Organization

1996

Generic protocol for population-based surveillance of Haemophilus influenzae type b.

Available http://www.who.int/vaccines-documents/DocsPDF/www9723.pdf. Accessed 6

March 2008

46. Pan American Health Organization

1998

Central America Meeting initiates surveillance system for Hib and

Streptococcus pneumoniae.

EPI Newsletter

20

4

47. KellyDFMoxonERPollardAJ

2004

Haemophilus

influenzae type b conjugate vaccines.

Immunology

113

163

174

48. Public Health Agency of Canada

2006

Invasive Haemophilus

influenzae disease in Manitoba in the post-vaccination era suggests a

changing epidemiology.

Can Commun Dis Rep

32

125

130

49. McVernonJAndrewsNSlackMPRamsayME

2003

Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with

acellular pertussis.

Lancet

361

1521

1523

50. HeathPTRamsayME

2003

Haemophilus

influenzae type b vaccine—Booster campaign.

BMJ

326

1158

1159

51. RamsayMEMcVernonJAndrewsNJHeathPTSlackMP

2003

Estimating Haemophilus

influenzae type b vaccine effectiveness in England and Wales by use of

the screening method.

J Infect Dis

188

481

485

52. JohnsonNGRuggebergJUBalfourGFLeeYCLiddyH

2006

Haemophilus

influenzae type b reemergence after combination immunization.

Emerg Infect Dis

12

937

941

53. HowieSRAntonioMAkisanyaASambouSHakeemI

2007

Re-emergence of Haemophilus

influenzae type b (Hib) disease in The Gambia following successful

elimination with conjugate Hib vaccine.

Vaccine

25

6305

6309